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LAMBERT, M. P., S. SABO, C. ZHANG, S. A. ENAM AND W. L. KLEIN. Constitutive Alzheimer's-type tauepitopes in
a neuritogenic rat CNS cell line. NEUROBIOL AGING 16(4) 583-589, 1995. -Paired helical filaments (PHFs) of Alzheimer's 
disease (AD) largely comprise hyperphosphorylated forms of the cytoskeletal protein tau. AD-type tau phosphoepitopes, detected 
by various monoclonal antibodies, are absent from normal adult neurons, but recent studies have shown that their expression 
may contribute to neuritogenesis and axon differentiation i the developing nervous ystem. Therefore, we have examined a 
brain nerve cell line that is spontaneously neuritogenic for possible xpression of AD-type tau epitopes. The neuritogenic rat 
brain cell line B103 was found to constitutively produce two AD-related epitopes of tau, detected by cellular immunofluores- 
cence studies with the PHF-1 and Alz-50 monoclonal ntibodies. Biochemical studies howed that the antibodies bound to pro- 
teins within the molecular weight range xpected for phosphorylated tau isoforms. Further verification was established by use 
of tau antisense oligomers, which eliminated cellular immunofluorescence du to the AD-related monoclonals and polyclonal 
anti-tau but did not eliminate fluorescence due to anti-tubulin. Cells treated with tau antisense were not neurite-free. Neurites 
that remained, however, were abnormal, generally short and wavy in appearance. Cellular distribution of the tau epitopes was 
found to be particularly interesting. Alz-50 recognized only cytoplasmic tau whereas PHF-1 recognized nuclear tau as well as 
cytoplasmic. Thus, the two epitopes are morphologically segregated within the cell. Because subcellular segregation f tau is 
compromised in Alzheimer's disease, mechanisms that segregate AD-type phosphotau epitopes in Bi03 cells may have relevance 
to this neurodegenerative disorder. 
Alzheimer's disease PHF-1 A lz -50  Antisense Tau protein Nuclear tau Neuroblastoma Cell line 
PAIRED helical filaments (PHFs) are known to be the prin- 
cipal structures of neurofibrillary tangles, a neuronal abnor- 
mality characteristic of Alzheimer's disease (AD) (46). PHFs 
comprise aberrantly phosphorylated forms of the cytoskeletal 
protein tau (14,35,28). Tau normally can exist in various states 
of phosphorylation, but the level of phosphorylation is consider- 
ably elevated in Alzheimer's-afflicted brain (23,26,17). Various 
phosphoepitopes found in Adzheimer's-type tau can be discerned 
by monoelonal ntibodies, a number of which have been raised 
against paired helical f'daments obtained from Alzheimer's brain 
tissue. Two of these antibodies, Alz-50 (51) and PHF-1 (20,21,22), 
have been found to be highly specific for degenerating eurons 
in the adult human brain (119,27,13). The Alz-50 epitope is at 
the amino terminal of tau. It comprises amino acids 2-10 of 
tau (numbering based on the longest form of adult human tau), 
a sequence that appears to be conformationally sensitive to 
the hyperphosphorylation associated with AD tan (32,16). The 
PHF-1 epitope is carboxy to the microtubule binding domains 
and depends on phosphorylation f ser396 in AD tau (4). Alz- 
ITo whom correspondence should be addressed. 
50 and PHF-1 epitopes also are found transiently in the devel- 
oping brain where their expression has been attributed to the 
massive nerve cell death that occurs during embryogenesis and 
brain development (reviewed in 5). These epitopes also can be 
induced in mature neurons that are degenerating due to experi- 
mental manipulations (41,8). 
The AD-type tau epitopes, however, are not always associ- 
ated with cell death. Recent studies of the PHF-I phosphotau 
epitope in developing chick brain neurons, for example, have 
shown it is expressed transiently by viable cells undergoing neu- 
ritogenesis and axon differentiation. The PHF-I Alzheimer's- 
type posttranslational modification of tau thus is highly conserved 
in evolution (43), complementing the highly conserved nature 
of tau itself (34), and is linked to neuritogenesis in immature 
neurons. 
Because AD-type tau phosphoepitopes can occur in viable 
immature neurons, they also are likely to occur in cloned nerve 
cell lines, which typically express multiple features of immature 
neurons. Such cell lines provide homogeneous experimental sys- 
tems, and they would be of use for investigations of the regulatory 
cell biology of Alzheimer's type tau phosphorylation. The current 
work has used the PHF-I and Alz-50 antibodies to investigate 
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tau epitopes expressed by the B103 rat nerve cell line. This line 
is of particular interest because it is spontaneously neuritogenic 
and is derived from the central rather than the peripheral ner- 
vous system (47). Results here show that the B103 rat ceils con- 
stitutively produce both the Alz-50 and PHF-I tau epitopes. The 
Alz-50 epitope is exclusively extranuclear, but the PHF-1 epitope 
is abundant inthe nuclear as well as extranuclear compartments. 
METHOD 
Cell Culture 
The B103 rat CNS cell line was a generous gift of D. Schubert 
of the Salk Institute, CA. Cultures are maintained in Dulbecco's 
Modified Eagle medium, antibiotics (streptomycin, penicillin, 
and fungizone, Gibco/BRL), and 10o7o fetal calf serum (Gibco/ 
BRL). For experiments, cells are plated on poly L-lysine-coated 
glass coverslips or Permanox LabTek plates (8 wells/plate, 
Nunc) at a density of 9 x 105 cells/cm 2 in a total volume of 
0.4 ml Cells are allowed to grow for 24 h before fixing. 
Immunocyt ochemistry 
Cells are fixed with 3.7o70 formaldehyde for 15 min at 37°C 
and permeabilized with 0.1°70 Triton X-100 for 5 min at room 
temperature. After washing with PBS containing l°T0 bovine 
serum albumin and 1% DMSO (PBS+), the cells are blocked 
with 10070 normal goat serum in PBS+ for 15 min. After another 
wash with PBS+, primary antibodies (PHF-1, Alz-50, and oth- 
ers) are added and allowed to react for 1.5 h at 37°C. After 
washing for 3 x 5 min with PBS+, FITC-conjugated anti-mouse 
IgG is added and allowed to react for 1.5 h in the dark. A final 
3 x 5 min wash with PBS+ and then one with PBS are done 
before mounting. Images are taken using a Hamamatsu 10-bit 
digital CCD camera with the MetaMorph imaging system (Uni- 
versal Imaging, Westchester, PA) on a Nikon Diaphot micro- 
scope equipped with epifluorescence capability. The MetaMorph 
system is also used to analyze the images for fluorescence inten- 
sity. PHF-1 (2.7 mg/ml) and Alz-50 (300/~g/ml) monoclonal 
antibodies were generous gifts of Jonathan Chong of Abbott 
Laboratories. They were used at 1:200 and 1:100 dilution, re- 
spectively, for immunocytochemistry and1:4000 for immuno- 
blots. Polyclonal anti-tau (against embryonic chick brain) was 
obtained from Sigma Chemical and used at 1:200 for immuno- 
cytochemistry and 1:4000 for immunoblots. This antibody does 
not cross-react with MAPI, MAP2, and tubulin, according to 
the company literature, and shows wide cross-reactivity amongst 
mammalian species (43,44). Polyclonal anti-tubulin (against 
embryonic chick brain) was obtained from ICN Biomedical, and 
used at 1:200. Tau-1 antibody was obtained from Boehringer 
Mannheim and used at 1:1000. 
Radioimmunoprecipitation Assay 
Cultures are grown as described for 24 h in a 60 mm dish. 
After rinsing with Hanks basic salt solution (37C, Gibco/BRL) 
and met/cys free DMEM (ICN, supplemented with 0.584 mg/ml 
glutamine) at37 °C, cells are incubated inthe met/cys free DMEM 
for 20 min. 150 mCi of 35S-methionine/cysteine (NEN, Ex- 
press) is added and the culture is grown overnight at 37C. After 
removal of the medium and two washes with chilled PBS, cells 
are harvested in 10 mM Tris-HCl, pH 7.4 containing 0.8 M 
NaC1, 3 mM EGTA, and 1 mM PMSF (fresh). After brief 
homogenization, the cell lysate is centrifuged at 30,000 × g 
for 20 min at 4°C. The supernatant cell lysate can be frozen at 
this point. 100 izl of lysate is used for each precipitation. 5/~1 
of PHF-I antibody (4.6 mg/ml) is added to the lystate and in- 
cubated for 1.5 h on ice. Meanwhile, a solution of protein A 
Sepharose isprepared in PBS containing 0.1°70 SDS, 1°70 Triton 
X-100, fresh deoxycholate, PMSF and aprotinin (PBS-TDS). 
200/d of protein A Sepharose is added to each sample and the 
sample is shaken at 1600 rpm for 1.5 h at 4°C. The Sepharose 
is then washed 3 x with PBS-TDS. 25 #1 of Laemmli buffer (30) 
is added to each sample and the sample is boiled for 5 min. 
Samples are then centrifuged and run on 8°7o SDS-PAGE gels 
(Novex). The gel is fixed in 10°70 acetic acid and 2507o isopro- 
panol for 30 min and soaked in Amplify (Amersham) for 30 min 
before being dried and exposed to X-ray film. 
AIz-50 Immunoprecipitation 
Cells are grown in poly L-lysine-coated 60 mm dishes for 
24 h and harvested with cold PBS and 0.02°70 EDTA. Then cells 
are briefly centrifuged and lysed with lysis buffer (150 mM 
NaC1; 50 mM Tris-HCl, pH 7.5; 1°70 Triton x 100; 0.1070 SDS; 
2 mM EDTA; added cocktail of protease inhibitors before use: 
2 mM PMSF, 0.2 TIU/ml aprotinin, 1 mg/ml leupeptin and 
50 mM NaF, 1 070 deoxycholate acid, 30 mM NaH2PO4). After 
centrifugation at 14,000 × g for 10 min, the supernatant is 
assayed for protein content, and then stored in 100/zg aliquots. 
For immunoprecipitation, 2 t~lof Alz-50 antibody isadded and 
allowed to incubate for 2 h on ice. Then, 200 Itl of protein A 
Sepharose prewashed with lysis buffer is added to each tube 
and the tube is shaken in the cold for 1.5 h. Unbound proteins 
are removed by 4 washes with lysis buffer. Bound proteins are 
solubilized in 20/zl Laemmli buffer (30), boiled for 5 min, sep- 
arated by electrophoresis on a 14°70 SDS-PAGE gel (Novex), and 
then transferred tonitrocellulose using a Hoeffer transfer appa- 
ratus. The nitrocellulose is then blocked for 2 h in PBS+ 0.1 070 
Tween 20 and 3°70 nonfat milk incubated with Alz-50 antibody 
(1:100 in PBS + 0.1070 Tween 20) for 1 h, washed 3x 15 min with 
PBS+ 0.1 070 Tween 20, and incubated with mouse IgG second- 
ary antibody (Vector Laboratories, Inc) for 30 min. After wash- 
ing, bound proteins are treated with ABC reagent for 30 min and 
visualized with DAB. 
ECL immunoblot and immunoprecipitation. Cells were 
grown in 60 mm dishes in DMEM, 10070 FCS, for 24 h, and har- 
vested in 0.01 M Tris, pH 7.4, supplemented with 1 mM EDTA, 
1 mM EGTA, 0.15 M NaC1, 1°70 Triton X-100, and a cocktail 
of protease inhibitors made up fresh (2 mM PMSF, 0.2 TIU/ml 
aprotinin, 1mg/ml eupeptin, 50 mM NaF, and 1 mg/ml pep- 
statin A). Cells were lysed by homogenization a d the protein 
content was determined. For an immunoblot, 20 #g of protein 
was added to an equal volume of Laemmli buffer and boiled for 
5 min. This sample was then loaded on an 8°70 polyacrylamide 
gel (Novex) and electrophoresed under denaturing conditions. 
The separated proteins were then transferred toa nitrocellulose 
membrane in the cold using a Hoeffer transfer apparatus. The 
membrane was then washed, blocked with 10°70 nonfat dry milk 
and probed with primary antibody for 1.5 h. After extensive 
washing, the antibody was conjugated toHRP-labeled second- 
ary for 1 h and visualized with ECL reagents. For an immuno- 
precipitation, 250 izg of protein was first precleared with Pro- 
tein A Sepharose which has been washed with PBS containing 
1°70 Triton-X-100, 0.1070 SDS, 1°70 BSA, and 5 mg/ml fresh de- 
oxycholate for 30 min. Primary antibody (13/~g) was then added 
and the solution allowed to sit on ice for 1 h with occasional 
shaking. Protein A Sepharose was then added and the solution 
was shaken at 1600 rpm overnight at 4°C. The Sepharose was 
precipitated by centrifugation a d then washed three times with 
the above collection buffer to remove unbound proteins. Bound 
proteins were then solubilized in 25 of Laemmli buffer by boil- 
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ing for 5 min. The solution was briefly centrifuged and the entire 
supernate was loaded on an 8% Novex gel and electrophoresed 
as described above. Visualization of the separated, transferred 
proteins was also as described above, using the ECL protocol. 
A n tisense Addit ion 
Cultures are plated at 2 × 105 cells/ml in a total volume 
of 0.2 ml/well in DMEM supplemented with the N2 mixture of 
Bottenstein and Sato (2). A :25 base deoxyoligonucleotide corre- 
sponding to the inverse complement of the sequence from -14 
to + 11 of rat tau (generously provided by Abbott Laboratories) 
is added to the medium at 50/~M concentration 10rain after 
plating and at 20-h intervals thereafter. At 60 h, cultures are 
fixed and permeabilized for 5 min with 0.2% Triton X-100. They 
are double-labeled for PHF-I and tubulin or PHF-1 and tau 
as described above. The secondary antibodies used are FITC- 
conjugated anti-rabbit IgG and Texas Red-conjugated anti- 
mouse IgG. 
RESULTS 
The B103 rat neuroblastoma cell line, derived from a rat CNS 
tumor, has various enzymatic characteristics of neuronal cells 
B 
D 
FIG. 1. PHF-1 and Alz-50 immunoreactivity are present innewly plated 
B103 cells. (A,B) Phase and fluorescent micrographs, respectively, of 
PHF-1 immunoreactivity in B 103 cells; (C,D) Phase and fluorescent 
micrographs, respectively, of Alz-50 immunoreactivity in similar cells. 
Arrow indicates long process with more intense PHF-1 immunoreactiv- 
ity. Bar in (D) equals 25 microns. B103 cells were cultured and immu- 
nostained for PHF-1 and Alz-50 tau as described inthe Method section. 
and spontaneously produces neurites in culture (47). Because 
axon formation and differentiation correlate with PHF-I tau 
expression i  the developing CNS, we asked if the B103 cell 
line might also express AD-related tau epitopes. B103 cells 
were grown for 24 h, fixed, and probed for these epitopes with 
PHF-1 or Alz-50 monoclonal ntibodies. Visualization was with 
FITC-conjugated anti-mouse IgG. As shown in Fig. 1, both 
PHF-1 and Alz-50 antigens were expressed strongly in every cell 
observed, both in the cell bodies and neuritic processes. Neu- 
ritic expression of PHF-1 tau was uniform out to the growth 
cone area, although as cell polarity developed, PHF-1 tau ap- 
peared more abundant in the thin, axon-like neurite (Fig. IB, 
arrow). Alz-50 staining was stronger in proximal areas of the 
neurite, in many instances tapering off near the growth cone, 
with no evidence of polarity. 
Of particular interest, the location of these tau antigens 
differed within the soma. The PHF-1 epitope was found in 
both the nucleus and cytoplasm, while the Alz-50 epitope was 
excluded from the nucleus. Antigens to polyclonal tau antibody 
were found in all cellular compartments (11, see also the tau 
sense control in Fig. 4F). Nuclear PHF-1 immunoreactivity was 
relatively more abundant than cytoplasmic, although the dif- 
ference in intensity may be due partially to the relative thick- 
ness of the nucleus. In addition, several days after plating, two 
populations of cells could be observed, those which had both 
nuclear and cytoplasmic PHF-I labeling and those which had 
only cytoplasmic labeling (data not shown). The decrease in 
nuclear PHF-1 immunoreactivity did not correlate with any 
apparent morphological property. Alz-50 immunofluorescence 
did not show any changes with respect to location or intensity 
during this time. 
The Alz-50 antibody recognizes an epitope that depends on 
the 2-10 amino acid residues of tau (16). To verify that Alz-50 
immunostaining found in B103 cells is also due to tau, proteins 
from B103 cell lysate were immunoprecipitated with Alz-50 anti- 
body. This immunoprecipitate was then solubilized, separated 
by electrophoresis and reprobed with Alz-50 antibody. The re- 
sult is shown in Fig. 2. Three proteins in cell lysate reacted with 
the Alz-50 antibody. Their apparent molecular weights are ap- 
proximately 51, 53, and 60 kDa. The two lower bands are in the 
range of fetal tau (29,15); the upper band is that of the lowest 
molecular weight form of PHF-tau (28,17,35). 
Because the calcium ionophore A23187 has been shown to af- 
fect the expression of Alz-50 in hippocampal cells (41), the effect 
of this agent on BI03 cells was also assessed. A concentration- 
dependent morphological effect was seen after 90 rain of incu- 
bation, with 5 ~M ionophore causing a retraction of neurites 
while 0.5 ~M had no effect (11, data not shown). Cell bodies 
changed from a rounded shape to one more triangular or fusi- 
form and the neurites assumed a dystrophic or wavy appearance. 
In the presence of 50 #M ionophore, most of the cells detached 
from the substratum. The remaining attached cells had almost 
completely retracted neurites. Despite significant morphologi- 
cal changes, Alz-50 immunofluorescence wasunchanged. 
PHF-tau proteins, including those recognized by the PHF-1 
antibody, have molecular weights in the 60-68 kDa range (28, 
17,35). The PHF-1 antibody also recognizes an epitope in fetal 
tau, the smallest form of tau with a molecular weight of 55- 
58 kDa (4,8) and epitopes in cultured peripheral neuroblastoma 
cells from 50-58 kDa (44,36,40,11). Attempts to analyze the 
Mr of the PHF-1 antigen in B103 cell lysate by western blot 
showed no specific bands. Therefore, a more sensitive radio- 
immunoprecipitation analysis was performed. BI03 cells were 
grown overnight in cys/met free medium with 35S-methionine. 
Protein was precipitated from cell lysate using the PHF-1 anti- 
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FIG. 2. Alz-50 immunoblot fB103 cell ysate shows three bands in the 
molecular weight range of 50 to 60 kDa. Left: molecular weight stan- 
dards. Lane A: Alz-50 antibody, Lane B: No primary. Arrows indicate 
the bands precipitated by the Alz-50 antibody at approximately 51,53, 
and 60 kDa, respectively. 
body and adsorption to Protein A Sepharose. The major specific 
protein which was immunoprecipitated by the PHF-1 antibody 
had a molecular weight of 60 kDa and was not present when 
the primary antibody was omitted from the procedure (Fig. 3). 
Although multiple forms of the tau protein were not observed, 
the molecular weight was in the range for adult phosphorylated 
97 
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FIG. 3. RIPA analysis hows a60 kDa band with the PHF-1 antibody 
in B103 cells grown for 24 h. Left: molecular weight standards. Lane A: 
PHF-1 antibody, Lane B: buffer alone. Arrow indicates the major 60 kDa 
band precipitated with PHF-I antibody. 
tau. Because the band found with radioimmunoprecipitation 
was faint and immunoblots were unsuccessful, additional stud- 
ies were done to verify the nature of PHF-1 immunoreactivity 
by eliminating all tau proteins from the cells by transiently in- 
troducing antisense tau DNA. Previous work showed that tau 
antisense deoxyoligonucleotides administered from the time of 
plating eliminated tau expression i cultured cerebellar macro- 
neurons and caused them to maintain an array of minor neurites 
without forming morphologically distinct axons and dendrites 
(7,6). In these same cells, exposure to tau antisense after estab- 
lishment of an axon-like neurite caused the retraction of this 
neurite. To determine if tau antisense deoxyoligonucleotides 
caused any changes in BI03 cultures, cells were given a 25 base 
deoxyoligonucleotide corresponding to the inverse complement 
of the sequence from -14 to + 11 of rat tau. After 60 h, cultures 
were fixed and processed for immunofluorescence using vari- 
ous antibodies. Cells administered tau antisense deoxyoligo- 
nucleotides had only minor neurites (Fig. 4A), most of which 
appeared wavy or abnormally shaped, whereas cells adminis- 
tered tau sense deoxyoligonucleotides hadessentially normal 
neurites (Fig. 4 B,D,F,H) compared to no addition controls. 
Compared to cells given tau sense deoxyoligonucleotides, the 
cells given tau antisense had dramatically decreased PHF- 1 and 
polyclonal tau staining (Fig. 4 C,D,E,F). Nuclear as well as cyto- 
plasmic staining was eliminated. In contrast, au antisense had 
no effect on immunolabeling forthe cytoskeletal protein tubu- 
lin, illustrating selectivity of the response (Fig. 4 G,H). Note 
that the apparent nuclear staining for tubulin in occasional cells 
was due to label associated with a spindle apparatus; although 
the BI03 cells spontaneously make neurites, they are not post- 
mitotic. Absence of PHF-I and tau immunoftuorescence but 
retention of tubulin staining strongly suggest that the immuno- 
fluorescence s en with the PHF-1 antibody isdue to tau protein. 
This conclusion isverifed by the nuclear immunoprecipitation 
experiment presented next. 
The nuclear concentration f PHF-1 tan immunostaining 
and its lack of reaction in western blots led us to the specula- 
tion that PHF-1 antibody was reacting with nuclear tau. Accord- 
ingly, a nuclear fraction prepared by the procedure of Loomis 
et al. (38), was probed with antibody against polyclonal tau; 
additionally, PHF-l-reactive protein was immunoprecipitated 
from the nuclear fraction and probed with polyclonal tau anti- 
body. The polyclonal tau antibody used for these experiments 
previously has been characterized byPope et al. (44) and shown 
to specifically recognize tau isoforms cross-reactive with PHF-1 
and Tau-l. As shown in Fig. 5, the polyclonal tau antibody rec- 
ognized tau in the B103 nuclear extract (Lane 2), with the high- 
est of three molecular weight forms present in greatest amount. 
Most important, the proteins that were immunoprecipitated 
from the nucleus by the PHF-1 tau antibody also were recog- 
nized by the polyclonal tau antibody (Lane 3). Again, the most 
prominent form was the highest molecular weight band at ap- 
proximately 60 kDa. The total number of forms recognized 
cannot yet be determined because the regularity of the bands 
indicate some degradation may have taken place. As expected, 
proteins from the whole cell lysate (Lane 1) also were recognized 
by polyclonal tau antibody. In a separate gel, both the nuclear 
extract and the total ysate also gave a positive signal with Tau- I 
antibody (data not shown). Results were similar to polyclonal 
anti-tau in the nuclear extract, with the higher of two molecu- 
lar weight forms more prominent. The immunoprecipitation and
immunoblot data thus verify that BI03 cells express in their 
nucleus a PHF-l-reactive form of tau protein. 
Several other cell lines also were examined for PHFl-tau im- 
munofluorescence (11, data not shown). The F3 variant of PCI2 
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FIG. 5. Nuclear proteins immunoprecipitated with PHF-I are recog- 
nized by polyclonal tau antibody. Lane 1:BI03 whole cell lysate was 
immunoblotted with polyclonal nti-tau. Lane 2: Proteins from a nuclear 
fraction of B103 cells prepared according to Loomis et al. (38) were 
immunoblotted with polyclonal anti-tau. Lane 3: Another aliquot of 
this fraction was immunoprecipitated with PHF-1 antibody and then 
reprobed with polyclonal nti-tau. Molecular weight markers are shown 
on the right. The results indicate cross reactivity is seen between nuclear 
tau and PHF-1 antibody. 
FIG. 4. Exposure to antisense :Eau in the medium causes loss of neurites 
and loss of immunolabeling after 60 h. B103 cells were plated on poly 
L-lysine and exposed to sense or antisense tau DNA (50 #M) for 60 h 
before fixing and observation with the Diaphot. (A,B) Phase micro- 
graphs: antisense and sense tatn, respectively; (C,D) PHF-I tau immu- 
nofluorescence: antisense and sense tau, respectively• (E,F) Polyclonal 
tau immunofluorescence: anti,;ense and sense tau, respectively. (G,H) 
Tubulin immunofluorescence: antisense and sense tau, respectively. Note 
the absence of PHF-1 tau and polyclonal tau immunoreactivity with 
antisense tau DNA (C,E). Bar in (C) equals 50 microns. 
cells had very weak Alz-50 and PHF-1 labeling. The mouse 
neuroblastoma line N 1 E-115 had a heterogenous expression of 
Alz-50 tau, with some cell,; having high levels of antigen and 
others having relatively lower levels. The human euroblastoma 
HCN-IA cells, differentiated or un-differentiated, didnot ex- 
press Alz-50 or PHF-1 tau protein. The SH-SY5Y human euro- 
blastoma cell line spontaneously expressed the PHF-1 epitope 
(40), while NTera 2 cells expressed PHF-1 tau only after differ- 
entiation with retinoic acid (45). These findings demonstrate that 
expression of the PHF-1 and Alz-50 epitopes varies widely in 
different cell lines of neural origin. 
DISCUSSION 
Data presented here have shown that the PHF-1 and Alz-50 
epitopes of tau are present constitutively in B103 rat neuroblas- 
toma cells. The B103 cell line is of particular interest because 
of its CNS origin and its ability to spontaneously produce neu- 
rites. Several other lines that were examined also expressed the 
PHF-1 epitope. Only B103 cells, however, showed robust levels 
of Alz-50 immunoreactivity. The Alz-50 epitope was exclusively 
cytoplasmic; the PHF-I immunoreactivity occurred throughout 
the cytoplasm but also was found in the nucleus, where it showed 
cross-reactivity with nuclear tau. The data confirm that these 
Alzheimer's-type tau epitopes are not simply the products of 
dying cells. Of particular interest, their subcellular distribu- 
tion patterns indicate differences intrafficking and, presumably, 
function. 
AD-type tau epitopes have been seen previously in cell culture 
systems. Alz-50 immunoreactivity has been reported in associ- 
ation with various neurodegeneration paradigms (41). Recently, 
in rat hippocampal cells, Alz-50 immunoreactivity was found 
to increase during the degenerative cascade voked by 13/A4 pep- 
tides (49). A similar association with B/A4-evoked egeneration 
has been seen in postmitotic SH-SY5Y human neuroblastoma 
cells (31). Prior to degeneration, these various cell culture sys- 
tems expressed the Alz-50 epitope at low levels in contrast to 
B103 cells. The robust expression of Alz-50 tau in the B103 line 
shows that it is not exclusively the product of dying cells. Simi- 
lar to the association ofthe Alz-50 epitope with viable B103 cells, 
the expression of the PHF-1 epitope also is not dependent on 
neurodegeneration. In the developing CNS, PHF-1 tau localizes 
to immature axons of viable neurons developing invivo and in 
culture (43). A recent report also has shown that the PHF-1 epi- 
tope is spontaneously present in the LAN human euroblastoma 
cell line, where it is downregulated byheat shock (8). 
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Phosphorylation, including the sort seen in Alzheimer's- 
afflicted neurons (42,39), decreases the ability of tau to stabi- 
lize microtubules, thereby increasing cytoskeletal plasticity. This 
phenomenon applies to the PHF-1 epitope (4) as well as other 
sites of tau phosphorylation (1,18,27). Excessive destabilization 
may give rise to the dystrophic neurites found in AD brain tis- 
sue. Physiologically, phosphorylation-evoked cytoskeletal plas- 
ticity is associated with mitosis (48) as well as neuritogenesis. 
Available data suggest he kinase cascades of either mitosis or 
neuritogenesis could lead to elevated levels of tau phosphory- 
lation. In proliferating SH-SY5Y human neuroblastoma cells, 
PHF- I  immunoreactivity varies as a function of the cell cycle, 
with upregulation observed at mitosis (44). In differentiated 
SH-SY5Y cells, stimulation of integrins, a known neuritogenic 
receptor, causes a marked increase in PHF-1 immunofluores- 
cence (40). In vitro experiments have shown that kinases cou- 
pled to the cell cycle will phosphorylate tau, with cdc2 kinase 
and mitogen activated protein (MAP) kinase producing AD-type 
epitopes, including the PHF-1 epitope (33,10,9). Interestingly, 
cdc2 kinase, MAP kinase, and PHF-1 immunoreactivity all 
downregulate in vivo following neuronal differentiation (3,43, 
24). Similar decreases in cdc2 kinase and PHF-1 immunoreac- 
tivities have been observed in association with retinoic acid- 
induced differentiation i  neuroblastoma cell lines (12,40). In 
AD-brain, upregulation of cdc2 kinase (33) is consistent with 
the idea that postmitotic brain cells in AD may be responding 
aberrantly to a mitogenic signal. Ectopic mitogenic signals have 
been hypothesized to evoke apoptosis in postmitotic ells, such 
as neurons (25), and apoptosis has been linked to Alzheimer's 
pathogenesis n cell culture studies (37) 
It is not understood why tau is in the nucleus, nor why it con- 
tains the PHF-1 but not the Alz-50 epitope. Loss of immuno- 
fluorescence by antisense tau oligonucleotides eliminates the 
possibility that the immunoreactivity is an artifact. Nuclear tau 
previously has been reported to occur in proliferating primary 
cell cultures and in two cell lines (38,50). This tau was correlated 
with expression of a 2 kDa mRNA,  the untranslated region o1 
which was hypothesized to target the protein to regions and 
functions not associated with microtubules. The current results 
extend these previous observations by showing that nuclear tau 
is present in other human neural cell lines and is phosphorylated 
to generate an AD-type epitope. 
Nuclear tau and its phosphorylation may have a bearing on 
tau anomalies een in Alzheimer's disease. Normally in mature 
neurons, tau is an axonal protein, but in AD, hyperphosphor- 
ylated tau accumulates ectopically in the somatodendritic com- 
partment. Hypothetically, ectopic somatic tau in AD could 
derive from disruptions in pathways that transport au to the 
nucleus and cause its nuclear phosphorylation. The nature of 
such disruptions is unknown, but recent studies of B/A4-evoked 
neurodegeneration have shown that neuronal apoptosis, which 
leads to breakdown of nuclear structure, could be involved (37). 
The BI03 rat brain cell line should prove to be a useful model 
for future studies of the regulatory cell biology of tau transport 
and phosphorylation and their relationship to mechanisms of 
Alzheimer's pathogenesis. 
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